Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion

References

• Williard WC, Collin C, Casper ES, Hajdu SI, Brennan MF. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992; 175: 389–396
   PubMedGoogle Scholar
• Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumour necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106: 1776–1784
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006; 3: 94–103
   PubMedGoogle Scholar
• Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149–160
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006; 6: 6
   PubMedGoogle Scholar
• Eggimann P, Chiolero R, Chassot PG, Lienard D, Gerain J, Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995; 107: 1074–1082
   PubMed Web of Science ®Google Scholar
• Menon C, Ghartey A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann Surg 2006; 244: 781–791
   PubMed Web of Science ®Google Scholar
• de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000–1003
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006; 106: 156–162
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Ruegg C. Recombinant human tumor necrosis factor: An efficient agent for cancer treatment. Bull Cancer 2006; 93: E90–100
   PubMedGoogle Scholar
• Hehlgans T, Mannel DN. The TNF-TNF receptor system. Biol Chem 2002; 383: 1581–1585
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45–65
   PubMed Web of Science ®Google Scholar
• Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: Function, release and clearance. Crit Rev Immunol 1996; 16: 1–11
   PubMed Web of Science ®Google Scholar
• Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7: 231–240
   PubMedGoogle Scholar
• Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992; 90: 533–536
   PubMed Web of Science ®Google Scholar
• Godfried MH, van der Poll T, Weverling GJ, Mulder JW, Jansen J, van Deventer SJ, Sauerwein HP. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994; 169: 739–745
   PubMed Web of Science ®Google Scholar
• Kern WV, Engel A, Schieffer S, Prummer O, Kern P. Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis. Infect Immun 1993; 61: 5413–5416
   PubMed Web of Science ®Google Scholar
• Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991; 51: 5602–5607
   PubMed Web of Science ®Google Scholar
• Aderka D, Engelmann H, Shemer-Avni Y, Hornik V, Galil A, Sarov B, Wallach D. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992; 11: 157–159
   PubMedGoogle Scholar
• Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, Wallach D, Klausner J. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998; 101: 650–659
   PubMedGoogle Scholar
• Gerain J, Lienard D, Pampallona S, Baumgartner M, Ruegg C, Buurman WA, Eggermont A, Lejeune F. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine 1997; 9: 1034–1042
   PubMed Web of Science ®Google Scholar
• Lejeune F, Lienard D, Eggermont A, Schraffordt KH, Rosenkaimer F, Gerain J, Klaase J, Kroon B, Vanderveken J, Schmitz P. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J Infus Chemother 1995; 5: 73–81
   PubMedGoogle Scholar
• Boyum A. Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents. Scand J Clin Lab Invest Suppl 1968; 97: 31–50
   PubMedGoogle Scholar
• Taeger G, Grabellus F, Podleska LE, Muller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 2008; 24: 193–203
   PubMed Web of Science ®Google Scholar
• Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429–437
   PubMed Web of Science ®Google Scholar
• de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80: 161–166
   PubMed Web of Science ®Google Scholar
• ten Hagen TL, Eggermont AM. Changing the pathophysiology of solid tumours: The potential of TNF and other vasoactive agents. Int J Hyperthermia 2006; 22: 241–246
   PubMed Web of Science ®Google Scholar
• van Horssen R, ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397–408
   PubMed Web of Science ®Google Scholar
• Carroll NM, Elaraj DM, Puhlmann M, Weinreich DM, Turner EM, Xu H, Alexander HR, Jr. Alterations in tumor necrosis factor-induced endothelial cell procoagulant activity by hyperthermia. Int J Cancer 2004; 111: 457–462
   PubMedGoogle Scholar
• Diegeler A, Doll N, Rauch T, Haberer D, Walther T, Falk V, Gummert J, Autschbach R, Mohr FW. Humoral immune response during coronary artery bypass grafting: A comparison of limited approach, ‘off-pump’ technique, and conventional cardiopulmonary bypass. Circulation 2000; 102(Suppl. 3)III95–III100
   PubMedGoogle Scholar
• Bemelmans MH, Gouma DJ, Buurman WA. Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine 1994; 6: 608–615
   PubMed Web of Science ®Google Scholar
• Hoving S, Seynhaeve AL, van Tiel ST, aan de Wiel-Ambagtsheer G, de Bruijn EA, Eggermont AM, ten Hagen TL. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 2006; 17: 949–959
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Laplanche A, Lejeune F, Stoeckle E, Le Péchoux C, Vanel D, Terrier P, Lumbroso J, Ricard M, Antoni G, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-alpha be better?. Ann Oncol 2005; 16: 1061–1068
   PubMed Web of Science ®Google Scholar
• Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A. Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol Cell Physiol 2001; 281: C1173–C1179
   PubMed Web of Science ®Google Scholar
• Friedl J, Turner E, Alexander HR, Jr. Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: Evidence for disruption of vascular integrity via VE-cadherin down-regulation. Int J Oncol 2003; 23: 611–616
   PubMed Web of Science ®Google Scholar
• Gnant MF, Turner EM, Alexander HR, Jr. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. Cytokine 2000; 12: 339–347
   PubMed Web of Science ®Google Scholar
• Islam A, Adamik B, Hawari FI, Ma G, Rouhani FN, Zhang J, Levine SJ. Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex. J Biol Chem 2006; 281: 6860–6873
   PubMedGoogle Scholar
• Menschikowski M, Hagelgans A, Eisenhofer G, Siegert G. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Exp Cell Res 2009; 315: 2673–2682
   PubMed Web of Science ®Google Scholar
• Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599–607
   PubMed Web of Science ®Google Scholar
• Porteu F, Hieblot C. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem 1994; 269: 2834–2840
   PubMed Web of Science ®Google Scholar
• Hokland SL, Nielsen T, Busk M, Horsman MR. Imaging tumour physiology and vasculature to predict and assess response to heat. Int J Hyperthermia 2010; 26: 264–272
   PubMed Web of Science ®Google Scholar
• Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005; 21: 761–767
   PubMed Web of Science ®Google Scholar
• Vaupel PW, Kelleher DK. Pathophysiological and vascular characteristics of tumours and their importance for hyperthermia: Heterogeneity is the key issue. Int J Hyperthermia 2010; 26: 211–223
   PubMed Web of Science ®Google Scholar
• Horsman MR. Tissue physiology and the response to heat. Int J Hyperthermia 2006; 22: 197–203
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Poulson JM, Gaskin AA, Thrall DE, Page RL, Charles HC, MacFall JR, Brizel DM, Meyer RE, Prescott DM, et al. Temperature‐dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 2000; 46: 179–185
   PubMed Web of Science ®Google Scholar